TSE:APS

Aptose Biosciences Q3 2025 Earnings Results & Report

Aptose Biosciences logo
C$2.40 0.00 (0.00%)
As of 07/3/2026

Aptose Biosciences reported Q3 2025 earnings on November 13, 2025. The company reported EPS of -C$2.01.

Earnings Announcement Details

Quarter
Q3 2025
Time
After Market Closes

Aptose Biosciences EPS Results

Actual EPS
-C$2.01
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A
EPS Beat Rate
5 of last 8 quarters

Aptose Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Aptose Biosciences Q3 2025 Earnings FAQ

Aptose Biosciences (TSE:APS) reported earnings of -C$2.01 per share for Q3 2025. The report was announced on Thursday, November 13, 2025.

Aptose Biosciences Earnings Headlines

I'm handing you this stock today
Elon doesn't own the chip inside his Teslas or Starlink dishes. He licenses it from one little known public company. Now he's planning 1,000,000 AI satellites in orbit, and every one could pay this company a royalty. Analyst Dylan says the window to get in closes around December 8th, before new money floods into the buildout.tc pixel
See More Aptose Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Aptose Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aptose Biosciences and other key companies, straight to your email.

About Aptose Biosciences

Aptose Biosciences (TSE:APS), a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.

View Aptose Biosciences Profile